Denali Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 66 to 72.
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their largest runs. See if Denali Therapeutics can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While now is not an ideal time to invest, see if the stock is able to establish and enter a buying range in heavy volume.
Denali Therapeutics showed 0% earnings growth in the latest quarterly report, while sales growth came in at -100%.
The company holds the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
